c-erbB-2 expression and nuclear pleomorphism in canine mammary tumors

Brazilian Journal of Medical and Biological Research

Volumn 37, Issue 11, 2004, Pages 1673-1681

  Dutra, A P ^a   Granja, N V M ^b   Schmitt, F C ^c   Cassali, G D ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b A C CAMARGO CANCER CENTER   (Brazil)

^c UNIVERSITY OF PORTO   (Portugal)

Author keywords

Breast cancer; c erbB 2 expression; Canine mammary tumors; MIB 1 expression; Nuclear pleomorphism

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; KI 67 ANTIGEN;

ANIMAL TISSUE; ARTICLE; BREAST TUMOR; CANCER GRADING; CARCINOGENESIS; CONTROLLED STUDY; DOG; GENE EXPRESSION; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MITOSIS; NONHUMAN; QUANTITATIVE ANALYSIS; SCORING SYSTEM; SPECIES DIFFERENCE; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TUMOR DIFFERENTIATION;

ANIMALIA; CANIS FAMILIARIS;

EID: 9244248713     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2004001100013     Document Type: Article

References (40)

1. Bargman CI, Hung MC & Weinberg RA (1986). The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature, 319: 226-230.
2. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ulrich A & McGuire WL (1987). Human breast cancer: correlation of relapse and survival with amplification of the Her-2 neu oncogene. Science, 253: 177-182.
3. Lodato RF, Maquire Jr HC, Greene MI, Weiner DB & LiVolsi VA (1990). Immunohistochemical evaluation of c-erbB-2 oncogene expression in ductal carcinoma in situ and atypical ductal hyperplasia of the breast. Modern Pathology, 3: 449-454.
4. Alfred DC, Clark GM, Molina R, Tandon AK, Schnitt SJ, Gilchrist KW, Osborne CK, Tormey DC & McGuire WL (1992). Overexpression of Her-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Human Pathology, 23: 974-979.
5. Bartkova J, Barnes DM, Millis RR & Gullick WJ (1990). Immunohistochemical demonstration of c-erbB-2 protein in mammary ductal carcinoma in situ. Human Pathology, 21: 1164-1167.
6. Lilleng R, Hagmar BM & Nesland JM (1992). c-erbB-2 protein and neuroendocrine expression in intraductal carcinoma of the breast. Modern Pathology, 5: 41-47.
7. Rachamandra S, Machin L, Ashley S, Monaghan P & Gusterson BA (1990). Immunohistochemical distribution of c-erbB-2 in in situ carcinoma: a detailed morphological analysis. Journal of Pathology, 161: 7-14.
8. Schmitt FC, Figueiredo P & Lacerda M (1995). Expression of c-erbB-2 protein and DNA ploidy in breast carcinogenesis. Archives of Pathology and Laboratory Medicine, 119: 815-820.
9. Ahern TE, Bird RC, Bird AE & Wolfe LG (1996). Expression of the oncogene c-erbB-2 in canine mammary cancers and tumor-derived cell lines. American Journal of Veterinary Research, 57: 693-696.
10. Rungsipipat A, Tateyama S, Yamaguchi R, Uchida K, Myoshi N & Hayashi T (1999). Immunohistochemical analysis of c-yes and c-erbB-2 oncogene products and p53 tumor suppressor protein in canine mammary tumors. Journal of Veterinary Medical Science, 61: 27-32.
11. Elston CW & Ellis IO (1991). Pathological prognostic factors in breast cancer: experience from a large study with long-term follow-up. Histopathology, 19: 403-410.
12. Bloom HJG & Richardson WW (1957). Histological grading and prognosis in breast cancer. A study of 1409 cases of which 359 have been followed for 15 years. British Journal of Cancer, 9: 359-377.
13. Genestie C, Zafrani B, Asselain B, Fourguet A, Rozan S, Validire P, Vincent-Salomon A & Satre-Garau X (1998). Comparison of the prognostic value of Scarff-Bloom-Richardson and Nottingham histological grades in the scores of 825 cases of breast cancer: major importance of the mitotic count as a component of both grading systems. Anticancer Research, 18: 571-576.
14. Tsuda H, Hirohashi S, Shimosato Y, Hirota T, Tsugane S, Watanabe S, Terada M & Yamamoto H (1990). Correlation between histologic grade of malignancy and copy number of c-erbB-2 gene in breast carcinoma. A retrospective analysis of 176 cases. Cancer, 65: 1794-1800.
15. Tsuda H, Tsugane S, Fukutomi T, Nanasawa T, Yamamoto H & Hirohashi S (1992). Prognostic factors for recurrent breast cancer: univariate and multivariate analyses including histologic grade and amplification of the c-erbB-2 proto-oncogene. Japanese Journal of Clinical Oncology, 22: 244-249.
16. Leal CB, Schimtt FC, Bento MJ, Maia NC & Lopes CS (1995). Ductal carcinoma in situ of the breast. Histologic categorization and its relationship to ploidy and immunohistochemical expression of hormone receptors, p53, and c-erbB-2 protein. Cancer, 75: 2123-2131.
17. Uehara T, Kaneko Y, Kanda N, Yamamoto T, Higashi Y, Nomoto C, Izumo T, Takayama S & Sakurai M (1990). c-erbB-2 and c-erbB-1 (ear-1) gene amplification and c-erbB-2 protein expression in Japanese breast cancers; their relationship to the histology and other disease parameters. Japanese Journal of Cancer Research, 81: 620-624.
18. Luna-Moré S, de los Santos F, Bretón JJ & Cañ adas MA (1996). Estrogen and progesterone receptors, c-erbB-2, p53 and Bcl-2 in thirty-three invasive micropapillary breast carcinomas. Pathology, Research and Practice, 192: 27-32.
19. Yang Q, Mori I, Sakurai T et al. (2001). Correlation between nuclear grade and biological prognostic variables in invasive breast cancer. Breast Cancer, 8: 105-110.
20. Moulton JE, Taylor DO, Dorn CR & Andersen AC (1970). Canine mammary tumors. Veterinary Pathology, 7: 289-296.
21. Misdorp W, Else RW, Hellmén E & Limpscomb TP (1999). Histological classification of the mammary tumors of the dog and the cat. In: World Health Organization. International Histological Classification of Tumors of Domestic Animals. 2nd series. Volume II. OMS, Geneva, Switzerland.
22. Rosen PP & Oberman HA (1993). Atlas of tumor pathology. In: Rosai J (Editor), Tumors of the Mammary Gland. Armed Forces Institute of Pathology, Washington, DC, USA, 157-203.
23. Cassali GD, Silva P, Rêma A, Gartner F, Gobbi H, Tafuri WL & Schmitt FC (2001). A new methodology for the improvement of diagnostic immunohistochemistry in canine veterinary pathology: automated system using human monoclonal and polyclonal antibodies. Arquivo Brasileiro de Medicina Veterinária, e Zootecnia, 53: 326-331.
24. Lebeau A (1953). L'âge du chien at celui de l'homme. Essai de statistique sur la mortalité canine. Bulletin de l'Academi Veterinaire de France, 26: 229-232.
25. van Diest JP, Baak JPA, Matze-Cok P et al. (11992). Reproducibility of mitosis counting in 2469 breast cancer specimens: Results from the multicenter morphometric mammary carcinoma project. Human Pathology, 23: 603-607.
26. Tsuda H, Akiyama F, Terasaki H, Hasegawa T, Kurosumi M, Shimadzu M, Yamamori S & Sakamoto G (2001). Detection of her-2/neu (c-erbB-2) DNA amplification in primary breast carcinoma. Interobserver reproducibility and correlation with immunohistochemical her-2 overexpression. Cancer, 92: 2965-2974.
27. Beeken SW, Grizzle WE, Crowe R, Conner MG, Weiss HL, Sellers MT, Krontiras H, Urist MM & Bland KI (2001). Molecular biomarkers for breast cancer prognosis: coexpression of c-erbB-2 and p53. Annals of Surgery, 233: 630-638.
28. Heinz NH, Leslie KO, Rogers LA & Howard PL (1990). Amplification of the c-erbB-2 oncogene and prognosis of breast adenocarcinoma. Archives of Pathology and Laboratory Medicine, 114: 160-163.
29. Mangili F, Sassi I, Di Rocco M, Leone BE, Garancini P & Santambrogio G (1996). Breast carcinoma detection with a combination of radiolabeled monoclonal antibodies. Promising results from immunohistochemistry studies. Cancer, 78: 2334-2339.
30. Gramlich TL, Cohen C, Fritsch C, DeRose PB & Gansler T (1994). Evaluation of c-erbB-2 amplification in breast carcinoma by differential polymerase chain reaction. Anatomic Pathology, 101: 493-499.
31. Leal C, Henrique R, Monteiro P, Lopes C, Bento MJ, De Sousa CP, Lopes P, Olson S, Silva MA & Page DL (2001). Apocrine ductal carcinoma in situ of the breast: histologic classification and expression of biologic markers. Human Pathology, 32: 487-493.
32. Reed W, Hannisdal E, Boehler PJ, Gundersen S, Host H & Nesland JM (2000). The prognostic value of p53 and c-erbB-2 immunostaining is overrated for patients with lymph node negative breast carcinoma. A multivariate analysis of prognostic factors in 613 patients with a follow-up of 14-30 years. Cancer, 88: 804-812.
33. Barbareschi M, Leonardi E, Mauri FA, Serio G & Dalla Palma PD (1992). p53 and c-erbB-2 protein expression in breast carcinomas. An immunohistochemical study including correlations with receptor status, proliferation markers, and clinical stage in human breast cancer. American Journal of Clinical Pathology, 98: 408-418.
34. O'Malley FP, Saad Z, Kervliet N, Doig G, Stitt L, Aisworth P, Hundal H, Chambers AF, Turnbull DI & Bramwell V (1996). The predictive power of semiquantitative immunohistochemical assessment of p53 and c-erbB-2 in lymph node-negative breast cancer. Human Pathology, 27: 956-963.
35. Révillion F, Bonneterre J & Peyrat JP (1998). ERBB2 oncogene in human breast cancer and its clinical significance (Review). European Journal of Cancer, 34: 791-808.
36. Murua E, Becker K, Bullerdiek J & Nolte I (2001). The canine ERBB2 gene maps to a chromosome region frequently affected by aberrations in tumors of the dog (Canis familiaris). Cytogenetics and Cell Genetics, 94: 194-195.
37. Pena L, Perez-Alenza MID, Rodríguez-Bertos A & Nieto A (2003). Canine inflammatory carcinoma: histopathology, immunohistochemistry and clinical implications of 21 cases. Breast Cancer Research and Treatment, 76: 141-148.
38. Sfacteria A, Bertani C, Costantino G, Del Bue M, Paiardini M, Cervasi B, Piedimonte A & De Vico G (2003). Cyclin D1 expression in precancerous and cancerous lesions of the canine mammary gland. Journal of ComParative Pathology, 128: 245-251.
39. Bell R (2002). What can we learn from herceptin trials in metastatic breast cancer? Oncology, 63 (Suppl 1): 39-46.
40. Campone M, Merlin JL & Fumoleau P (2003). Role of the combination of trastuzumab in the therapeutic management of cancer of the breast: from preclinical data to clinical application. Bulletin of Cancer, 90: 614-622.